CDMO
【中银国际：上调药明康德目标价至81港元 上调今明两年盈利预测】 金十数据3月21日讯，中银国际发表研究报告指，药明康德(02359.HK)核心业务(不包括新冠商业化项目)去年按年增长5.2%，TIDES收入按年增长70%；第四季净利润按季增长27%，收入按季增长10%，凸显强劲复苏趋势。受全球顶级制药公司强劲需求以及瑞士、美国和新加坡产能持续扩张的推动，公司订单量达到创纪录的493亿元，按年增长47%，高于去年首九个月的按年增长35%。展望2025年，该行料药明康德预计将重回两位数增长，收入预计按年增长10%至15%，达到415亿至430亿元之间，受惠TIDES和CDMO服务的强劲发展势头。该行将药明康德今明两年的盈利预测分别上调13%和26%，目标价由62港元上调至81港元，维持“买入”评级。
时间：2025-03-21 09:53:38 市场： 美股 综合 港股
Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of Its Convertible Notes in Connection With Completed Merger
时间：2025-02-05 23:45:17 市场： 美股 综合
Brock Pond Capital Partners: Urges Avid Bioservices to Remain Standalone Public Company Absent Improved Offer
时间：2024-11-13 22:11:50 市场： 美股 综合
Sector Update: Health Care Health care stocks rose late Tuesday afternoon with the NYSE Health Care Index adding 0.2% and the Health Care Select Sector SPDR Fund (XLV) increasing 0.4%.The iShares Biotechnology ETF (IBB) gained 0.2%.In corporate news, Avid Bioservices (CDMO) shares jumped 17% as RBC Capital Markets raised its price target to $12 from $8 after the company's bookings topped estimates.
时间：2024-09-11 03:26:23 市场： 美股 综合
Avid Bioservices Shares Jump as RBC Boosts Price Target After Bookings Beat Avid Bioservices (CDMO) shares jumped 19% in recent Tuesday trading as RBC Capital Markets raised its price target to $12 from $8 after the company's bookings topped the analyst's estimate.Bookings in fiscal Q1 at $66 million beat RBC's forecast of $36 million, the company's results showed Monday. "Improving bookings momentum" spurred the higher price target, RBS said, affirming its outperform rating on the stock.The company reiterated revenue guidance for fiscal 2025 of $160 million to $168 million, supported by growing bookings and backlog standing at $219 million, RBC said.Price: 10.62, Change: +1.67, Percent Change: +18.66
时间：2024-09-11 02:21:08 市场： 美股 综合